Development of an interview-based warfarin nomogram predicting the time spent in the therapeutic INR range: A cost-effective, and non- invasive strategy building from a cross sectional study in a low resource setting

被引:3
作者
Anand, Aishwarya [1 ]
Kumar, Rupesh [2 ]
Gupta, Ankur [3 ,7 ]
Vijayvergiya, Rajesh [3 ]
Mehrotra, Saurabh [3 ]
Lad, Deepesh [4 ]
Barwad, Parag [3 ]
Sharma, Swati [5 ]
Patil, Amol N. [1 ,6 ]
机构
[1] Postgrad Inst Med Educ & Res PGIMER, Dept Pharmacol, Chandigarh, India
[2] Postgrad Inst Med Educ & Res PGIMER, Dept Cardiothorac & Vasc Surg, Chandigarh, India
[3] Postgrad Inst Med Educ & Res PGIMER, Dept Cardiol, Chandigarh, India
[4] Postgrad Inst Med Educ & Res PGIMER, Dept Internal Med, Chandigarh, India
[5] Postgrad Inst Med Educ & Res PGIMER, Dept Expt Med & Biotechnol, Chandigarh, India
[6] PGIMER, Dept Pharmacol, Chandigarh 160012, India
[7] PGIMER, Dept Cardiol, Chandigarh, India
关键词
Warfarin nomogram; Percent time in therapeutic range; INR; ATRIAL-FIBRILLATION;
D O I
10.1016/j.ihj.2022.03.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A cross-sectional study was conducted to predict time in therapeutic range (TTR) using clinical history, examination, and socioeconomic data. Study included warfarin-receiving patients from outpatient-clinic. In 203 patients studied, mean warfarin start-dose was 2.55 mg/day and maintenance-dose/week was 30.79 mg. Body mass index (BMI) (p = 0.03), warfarin maintenance dose/day (p = 0.02), and comorbidity presence (p = 0.04) were significantly associated with TTR. Occupation (p = 0.53), income (p = 0.83), education (p = 0.55), and socioeconomic score (p = 0.73) showed non-significant association with TTR. A TTR predicting nomogram was built from clinical history and examination findings. (c) 2022 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:245 / 248
页数:4
相关论文
共 15 条
  • [1] Quality of anticoagulation with warfarin in rural Chhattisgarh, India
    Chebrolu, Puja
    Patil, Sushil
    Laux, Timothy S.
    Al-Hammadi, Noor
    Jain, Yogesh
    Gage, Brian
    [J]. INDIAN JOURNAL OF MEDICAL RESEARCH, 2020, 152 (03) : 303 - 307
  • [2] Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study
    Farsad, Bahram-Fariborz
    Abbasinazari, Mohammad
    Dabagh, Atousa
    Bakshandeh, Hooman
    [J]. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016, 10 (09) : FC4 - FC6
  • [3] Apixaban Compared With Warfarin for Stroke Prevention in Atrial Fibrillation Implications of Time in Therapeutic Range
    Gallego, Pilar
    Antonio Vilchez, Juan
    Lane, Deirdre A.
    [J]. CIRCULATION, 2013, 127 (22) : 2163 - 2165
  • [4] Warfarin initiation nomograms for venous thromboembolism
    Garcia, Pedro
    Ruiz, Wilson
    Munarriz, Cesar Loza
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (07):
  • [5] Systematic overview of warfarin and its drug and food interactions
    Holbrook, AM
    Pereira, JA
    Labiris, R
    McDonald, H
    Douketis, JD
    Crowther, M
    Wells, PS
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (10) : 1095 - 1106
  • [6] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
    Johnson, J. A.
    Caudle, K. E.
    Gong, L.
    Whirl-Carrillo, M.
    Stein, C. M.
    Scott, S. A.
    Lee, M. T.
    Gage, B. F.
    Kimmel, S. E.
    Perera, M. A.
    Anderson, J. L.
    Pirmohamed, M.
    Klein, T. E.
    Limdi, N. A.
    Cavallari, L. H.
    Wadelius, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (03) : 397 - 404
  • [7] Genetic and Nongenetic Determinants of Variable Warfarin Dose Requirements: A Report from North India
    Kaur, Navjot
    Pandey, Avaneesh
    Shafiq, Nusrat
    Gupta, Ankur
    Das, Reena
    Singh, Harkant
    Ahluwalia, Jasmina
    Malhotra, Samir
    [J]. PUBLIC HEALTH GENOMICS, 2021, : 52 - 60
  • [8] Warfarin Pharmacogenomics in Diverse Populations
    Kaye, Justin B.
    Schultz, Lauren E.
    Steiner, Heidi E.
    Kittles, Rick A.
    Cavallari, Larisa H.
    Karnes, Jason H.
    [J]. PHARMACOTHERAPY, 2017, 37 (09): : 1150 - 1163
  • [9] 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
    Kleindorfer, Dawn O.
    Towfighi, Amytis
    Chaturvedi, Seemant
    Cockroft, Kevin M.
    Gutierrez, Jose
    Lombardi-Hill, Debbie
    Kamel, Hooman
    Kernan, Walter N.
    Kittner, Steven J.
    Leira, Enrique C.
    Lennon, Olive
    Meschia, James F.
    Nguyen, Thanh N.
    Pollak, Peter M.
    Santangeli, Pasquale
    Sharrief, Anjail Z.
    Smith, Sidney C., Jr.
    Turan, Tanya N.
    Williams, Linda S.
    [J]. STROKE, 2021, 52 (07) : E364 - E467
  • [10] Kuruvilla M, 2001, Proc (Bayl Univ Med Cent), V14, P305